Dmitrii is a pharmacist. He received his PhD in Medicinal Chemistry (summa cum laude, 2017) from the University of Münster, Germany, where he was a fellow of the international Graduate School “Cells in Motion” - Cluster of Excellence. Under the supervision of Prof. B. Wünsch and Prof. R. Holl, his doctoral research focused on the design and synthesis of biologically active small molecules, including new antibiotics and tracers for positron emission tomography (PET). He subsequently undertook postdoctoral research at the University of Southern Denmark with Prof. T. Ulven (2017 - 2018), where he worked on Pd-catalysed carbonylative cross-coupling reactions and Medicinal Chemistry applications.

In 2018, Dmitrii established his independent research group at the University of Münster, where he completed his Habilitation in Pharmaceutical and Medicinal Chemistry (2025). His research programme focuses on the development of novel antithrombotic drugs, targeting blood coagulation factors and platelet receptors. His group integrates Organic Synthesis, microscale parallel synthesis, structure-based drug design, and biochemical and pharmacological evaluation to accelerate Drug Discovery. His work was funded by the German Research Foundation (DFG), and he is the recipient of the 2025 Innovation Award from the German Chemical and Pharmaceutical Societies.

In 2026, Dmitrii joined the School of Biological and Chemical Sciences at the University of Galway, relocating his research group from Germany. Beyond research, he is strongly committed to teaching and mentorship, with extensive experience delivering courses in Medicinal Chemistry, Organic Chemistry, and Stereochemistry, and supervising undergraduate, master’s, and doctoral researchers. His broader academic interests include interdisciplinary collaboration, training of early-career scientists, and the development of a supportive and inclusive research culture.

Dmitrii’s research focuses on the design and development of small-molecule therapeutics in medicinal and pharmaceutical chemistry, with a particular emphasis on antithrombotic drug discovery. His work integrates organic synthesis, microscale parallel synthesis, structure-based drug design, biochemical enzymatic assays, and blood coagulation tests to develop potent and selective inhibitors of blood coagulation factors and platelet receptors.

A central objective of his research programme is to address unmet clinical needs in thrombosis and haemostasis by establishing clear structure-activity relationships and enabling efficient lead optimisation. More broadly, Dmitrii is interested in interdisciplinary research at the interface of chemistry and biology and in advancing translational approaches to drug discovery.

Dmitrii’s teaching interests span Medicinal and Pharmaceutical Chemistry, Organic synthesis, Stereochemistry, and Drug Design, with a strong emphasis on research-led and practice-oriented learning. He is particularly interested in teaching enzyme inhibition, structure-activity relationships, and modern Medicinal Chemistry techniques, and in supervising undergraduate and postgraduate research projects within interdisciplinary chemical and health science programmes.

1. Development of small-molecule inhibitors of blood coagulation factor XIIa as novel and safer anticoagulant therapies.

2. Design and synthesis of small-molecule inhibitors targeting human plasma kallikrein for the treatment of hereditary angioedema.

3. Synthesis of peptidomimetic ligands targeting P2X1 ion channels to regulate platelet activation and thrombus formation.

4. Synthesis of covalent inhibitors of the SARS-CoV-2 main protease for antiviral drug discovery.

5. Design and synthesis of prostate-specific antigen (PSA) inhibitors as a non-hormonal male contraceptive strategy.